Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-932 MAD study in healthy adults, GAD and BPD
NCT06024239Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-932 in generalized anxiety disorder (GAD) and bipolar disorder (BD) (8 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Observed Plasma Concentration and 3 more. Started Aug 2023; status: completed.
02
Drugs
ABBV-932
03
Conditions
generalized anxiety disorder (GAD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT06024239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06024239.